在庫拠点

New Jersey, USA
Czech Republic, EU
Mumbai, India

* 在庫状況によります

Documentation

MSDSをダウンロード

サンプルCOAをダウンロード

内容: HPLC、MASS/LC-MS、1H NMR、FT-IR、含量、構造解析レポート（SER）、および製品に応じた追加分析データ。

118-00-3Adenosine EP Impurity H

● 在庫あり

カタログ番号:	VE007800
CAS番号:	118-00-3
分子式:	C10H13N5O5
分子量:	283.2 g/mol

見積もり依頼

RFQリストに追加

に関する追加情報 CAS 118-00-3

親薬物

Adenosine

IUPAC名

2-Amino-9-Beta-D-ribofuranosyl-1,9-dihydro-6H-purin-6-one

Pharmacopeial Synonyms

Guanosine

同義語

guanine riboside; vernine; Guanozin; Guanosin; 2-Amino-1,9-dihydro-9-beta-D-ribofuranosyl-6H-purin-6-one; Guanine-9-beta-D-ribofuranoside; 9-beta-D-Ribofuranosylguanine; Ribofuranoside, guanine-9, beta-D-; 2(3H)-Imino-9-beta-D-ribofuranosyl-9H-purin-6(1H)-one; 2-Amino-9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-purin-6(9H)-one; 2-Amino-9-beta-D-ribofuranosyl-1,9-dihydro-6H-purin-6-one; 9-.beta.-D-ribofuranosylguanine; [3H]-guanosine; Inosine, 2-amino; Guanine-9-ss–D-ribofuranoside; 9-beta-delta-ribofuranosyl-Guanine

SMILES

O=C1NC(N)=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@@H](CO)O3)O)O

InChI

InChI=1S/C10H13N5O5/c11-10-13-7-4(8(19)14-10)12-2-15(7)9-6(18)5(17)3(1-16)20-9/h2-3,5-6,9,16-18H,1H2,(H3,11,13,14,19)/t3-,5-,6-,9-/m1/s1

Shipping Condition

Ambient Temperature

説明

Adenosine EP Impurity H, identified as guanosine (CAS 118-00-3), is a structurally related nucleoside impurity encountered during adenosine synthesis and stability studies. Molecular formula C10H13N5O5 and exact mass 283.24 Da facilitate mass spectrometric identification with a characteristic [M+H]+ at m/z 284. Reversed-phase HPLC separates guanosine from adenosine with distinct retention behavior and UV absorbance near 254 nm, while 1H and 13C NMR confirm ribofuranosyl and guanine resonances. Water solubility and thermal decomposition profiles support analytical method development. Routine control by validated HPLC and MS methods ensures compliance with pharmacopoeial impurity limits.

References

Lanznaster, Débora, et al. “Guanosine: A Neuromodulator with Therapeutic Potential in Brain Disorders.” Aging and Disease, vol. 7, no. 5, 2016, p. 657, https://doi.org/10.14336/ad.2016.0208. ?